ObjectiveTo explore the value of ultrasomics in differential diagnosis of benign and malignant breast lesions of BI-RADS category 4.MethodsA total of 223 patients with breast lesions of BI-RADS category 4 confirmed by biopsy pathology in our hospital were collected prospectively

and they were divided into the training group（n=114

81 benign cases and 33 malignant cases）and validation group（n=109

70 benign cases and 39 malignant cases）.The ultrasomics score of breast lesion was established based on the training group. Receiver operating characteristic（ROC）curve of the ultrasomics score was drawn to quantitatively assess the differential diagnostic efficacy of benign and malignant breast lesions of BI-RADS category 4

the sensitivity and specificity were calculated and verified in the validation group.ResultsAmong the223 cases

malignancy accounted for 32.29%. The malignant proportions in the training and validation groups were 28.95%and 35.78%

respectively. The AUC with 95% confidence interval of the ultrasomics score in the training and validation groups were 0.826（0.743～0.909）and 0.810（0.723～0.898）

respectively. In the training group

the sensitivity and specificity of ultrasomics scores to distinguish benign and malignant breast lesions of BI-RADS category 4 lesions were 78.79% and81.48%

respectively. In the validation group

the corresponding sensitivity and specificity were 66.67% and 82.86%

respectively.ConclusionThe ultrasomics score has a certain value in differential diagnosis of breast lesions of BI-RADS category 4.